Related Experiment Video
Updated: Mar 19, 2026
08:12
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
6.1K
Biomarker in Colorectal Cancer
Marta Schirripa1, Heinz-Josef Lenz
1From the USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Cancer Journal (Sudbury, Mass.)
|June 25, 2016
Summary
Advances in metastatic colorectal cancer treatment have improved survival. However, identifying reliable biomarkers like RAS mutations, BRAF V600E, and microsatellite instability remains challenging due to disease heterogeneity.
Area of Science:
- Oncology
- Genetics
- Cancer Research
Background:
- Metastatic colorectal cancer (mCRC) treatment has significantly improved, with median survival now exceeding 30 months.
- Despite progress, identifying predictive and prognostic biomarkers for mCRC remains a critical challenge.
- Colorectal cancer (CRC) is characterized by significant heterogeneity and dynamic biological mechanisms.
Purpose of the Study:
- To review the discovery and role of key biomarkers in colorectal cancer: RAS mutations, BRAF V600E mutation, and microsatellite instability.
- To discuss the major challenges and pitfalls encountered in biomarker research for colorectal cancer.
- To propose future research directions for advancing biomarker discovery in this field.
Main Methods:
- Literature review focusing on the evolution of biomarker discovery in colorectal cancer.
- Analysis of the clinical significance of RAS mutations, BRAF V600E, and microsatellite instability.
- Discussion of methodological and biological challenges in biomarker research.
Main Results:
- Established the historical progression and current understanding of RAS, BRAF V600E, and MSI as CRC biomarkers.
- Highlighted the complexities arising from tumor heterogeneity and dynamism impacting biomarker utility.
- Identified key limitations and potential biases in current biomarker research strategies.
Conclusions:
- Biomarker identification in mCRC is crucial for personalized treatment despite significant challenges.
- Understanding the heterogeneity and dynamism of colorectal cancer is key to overcoming research pitfalls.
- Future research should focus on innovative strategies to refine biomarker discovery and clinical application for improved patient outcomes.
